首页> Frontiers in nuclear medicine> DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.

DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.

导出 LinkOut

翻译打印收藏纠错

第一作者： Tilmann,Grus

第一单位： Department of Chemistry-TRIGA Site, Johannes Gutenberg University, Mainz, Germany.

作者： Tilmann,Grus ^[1] ; Hanane,Lahnif ^[1] ; Nicole,Bausbacher ^[2] ; Matthias,Miederer ^[2] ; Frank,Rösch ^[1]

作者单位： Department of Chemistry-TRIGA Site, Johannes Gutenberg University, Mainz, Germany. ^[1] Department of Nuclear Medicine, University Medical Center Mainz, Mainz, Germany. ^[2]

关键词 PSMA bisphosphonate bone metastases lutetium-177 pamidronate prostate cancer

DOI 10.3389/fnume.2022.892147

PMID 39354968

发布时间 2024-10-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in nuclear medicine

2022年2卷

892147页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Frontiers in nuclear medicine

2022年2卷

892147页

检索历史清除

DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.

Frontiers in nuclear medicine

相似文献

同项目论文

Frontiers in nuclear medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.

Frontiers in nuclear medicine

相似文献

同项目论文

Frontiers in nuclear medicine

相关期刊

检索历史清除